Kevin Comar, MD
Gastroenterology · St Johns, FLNPI 1184832909
Payments from drug & device makers
Across 531 payments — averaging $592.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gyrus ACMI, Inc.$300K
- Alnylam Pharmaceuticals Inc.$5K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$970
- Johnson & Johnson$647
- Bristol Myers Squibb$557
- plus $4K from 28 others
What the payments were for
- Food & beverage$9,414100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gyrus ACMI, Inc. | 8 | $300,030 |
| Alnylam Pharmaceuticals Inc. | 2 | $5,260 |
| AbbVie(2 entities) | 200 | $3,295 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 56 | $970 |
| Johnson & Johnson | 42 | $647 |
| Bristol Myers Squibb | 38 | $557 |
| Sanofi | 20 | $419 |
| Lilly USA, LLC | 23 | $384 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $365 |
| Regeneron Healthcare Solutions, Inc. | 14 | $332 |
| Merck | 14 | $300 |
| QOL Medical, LLC | 10 | $285 |
| Pfizer | 15 | $284 |
| Gilead | 11 | $244 |
| Madrigal Pharmaceuticals | 2 | $158 |
| Ironwood Pharmaceuticals, Inc | 9 | $151 |
| Olympus America Inc. | 1 | $149 |
| Medtronic | 1 | $139 |
| Nestle Healthcare Nutrition Inc. | 5 | $87 |
| Redhill Biopharma Inc. | 5 | $86 |
| Intercept Pharmaceuticals, Inc. | 5 | $85 |
| Vivus LLC | 4 | $72 |
| Daiichi Sankyo Inc. | 4 | $62 |
| UCB, Inc. | 3 | $59 |
| Aimmune Therapeutics, Inc. | 3 | $51 |
| Shire North American Group Inc | 3 | $42 |
| Shionogi Inc | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| Novo Nordisk | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$314,711 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 182 | $5,160 |
| Mesalamine | 13 | $3,523 |
| Esomeprazole Magnesium | 36 | $3,070 |
| Omeprazole | 90 | $1,384 |
| Famotidine | 46 | $370 |
| Ondansetron OdtOndansetron | 12 | $250 |
| Dicyclomine Hcl | 13 | $211 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in St Johns
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
- Henry LevineOrlando$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.